NIVEN RALPH
SEC CIK 1168060 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | CSO | 6,209 | — | $989.3K | 32 | 2022-08-18 | 2024-02-05 |
Most active insiders at JBIO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Balta Elizabeth | See Remarks | — | — |
| 2 | Frohlich Tom | CEO, Dir | — | — |
| 3 | King Andrew James | See Remarks | — | — |
| 4 | Dahms Bradford D. | CFO | — | — |
| 5 | Fairmount Healthcare Fund II L.P. | Dir, 10% | — | — |
NIVEN RALPH made no open-market trades at JBIO in the last 12 months.
Transactions 32
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-07 | 2024-02-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +4,600 | 6,209 | +286% | +$9,284 |
| D | 2024-02-07 | 2024-02-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $17.45 | -4,600 | 1,609 | -74% | -$80.3K |
| DM | 2024-01-08 | 2024-01-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +4,600 | 6,209 | +286% | +$9,284 |
| DM | 2024-01-08 | 2024-01-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $19.15 | -4,600 | 1,609 | -74% | -$88.1K |
| DM | 2023-12-07 | 2023-12-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +4,600 | 3,009 | New | +$9,284 |
| D | 2023-12-07 | 2023-12-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $16.30 | -4,600 | 1,609 | -74% | -$75.0K |
| DM | 2023-11-27 | 2023-11-22 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +13.8K | 5,809 | New | +$27.9K |
| D | 2023-11-27 | 2023-11-22 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $15.00 | -13.8K | 1,609 | -90% | -$207.0K |
| DM | 2023-07-07 | 2023-07-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 3,859 | +140% | +$4,555 |
| DM | 2023-07-07 | 2023-07-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $17.29 | -2,250 | 1,609 | -58% | -$38.9K |
| D | 2023-06-07 | 2023-06-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $16.26 | -2,250 | 1,609 | -58% | -$36.6K |
| DM | 2023-06-07 | 2023-06-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 2,259 | +25,000% | +$4,555 |
| DM | 2023-05-09 | 2023-05-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $20.87 | -2,250 | 1,814 | -55% | -$46.9K |
| DM | 2023-05-09 | 2023-05-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 3,859 | +140% | +$4,555 |
| DM | 2023-04-07 | 2023-04-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $18.20 | -2,250 | 2,144 | -51% | -$40.9K |
| DM | 2023-04-07 | 2023-04-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 3,859 | +140% | +$4,555 |
| DM | 2023-03-08 | 2023-03-06 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $23.75 | -2,250 | 1,654 | -58% | -$53.4K |
| DM | 2023-03-08 | 2023-03-06 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 3,859 | +140% | +$4,555 |
| DM | 2023-02-08 | 2023-02-06 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 3,859 | +140% | +$4,555 |
| D | 2023-02-08 | 2023-02-06 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $24.27 | -2,250 | 1,609 | -58% | -$54.6K |
| DM | 2023-01-09 | 2023-01-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 2,259 | +25,000% | +$4,555 |
| D | 2023-01-09 | 2023-01-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $26.40 | -2,250 | 1,609 | -58% | -$59.4K |
| DM | 2022-12-07 | 2022-12-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 3,859 | +140% | +$4,555 |
| D | 2022-12-07 | 2022-12-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $17.38 | -2,250 | 1,609 | -58% | -$39.1K |
| DM | 2022-11-09 | 2022-11-07 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $19.19 | -2,250 | 1,609 | -58% | -$43.2K |
| DM | 2022-11-09 | 2022-11-07 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 2,259 | +25,000% | +$4,555 |
| DM | 2022-10-07 | 2022-10-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $15.75 | -2,250 | 1,800 | -56% | -$35.4K |
| DM | 2022-10-07 | 2022-10-05 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 2,259 | +25,000% | +$4,555 |
| D | 2022-09-07 | 2022-09-06 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $19.00 | -2,250 | 1,609 | -58% | -$42.8K |
| DM | 2022-09-07 | 2022-09-06 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 3,859 | +140% | +$4,555 |
| D | 2022-08-19 | 2022-08-18 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | S - Sale+OE | $21.18 | -2,250 | 1,609 | -58% | -$47.7K |
| DM | 2022-08-19 | 2022-08-18 | JBIO | Jade Biosciences, Inc. | NIVEN RALPH | CSO | M - OptEx | $2.02 | +2,250 | 2,259 | +25,000% | +$4,555 |
Purchase Sale Sale after option exercise All abbreviations